All In Biotech

BLA 017692 · Organon USA LLC

Pregnyl

Gonadotropin, Chorionic · Injection

Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Oct 20, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,292

340 Phase 3, 113 recruiting

FAERS reports

2,092

1,000 serious, 30 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 2, 2025.

INDICATIONS AND USAGE HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomical obstruction. In general, hCG is thought to induce testicular descent in situations when descent would have occurred at puberty. hCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following hCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 20, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • PREGNYL · GONADOTROPIN, CHORIONIC 10,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gonadotropin" as an intervention, any sponsor and status, largest first.

All 1,292 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome520
  • no adverse event226
  • product dose omission issue134
  • drug ineffective115
  • product packaging quantity issue101
  • product quality issue93
  • product use in unapproved indication87
  • inappropriate schedule of drug administration83
  • off label use79
  • ascites76
  • product dose omission73
  • abdominal distension71

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200510
20066
20075
200810
200913
201011
201118
201245
201339
201473
201548
201666
2017200
2018118
2019160
2020149
2021166
2022258
2023111
2024169
2025112
2026303

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pregnyl (Chorionic Gonadotropin, Human)

2024 spending

$330K

Beneficiaries

210

824 claims

Per beneficiary

$1,572

$145.37 per unit

View as table
YearSpending
2020$70,758
2021$126,709
2022$162,527
2023$254,690
2024$330,017

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,170 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.